Vaxil Bio Proposed Reverse Takeover With Copper Bullet Terminated and Update of Research Activities
Vaxil Bio Proposed Reverse Takeover With Copper Bullet Terminated and Update of Research Activities
Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States
不得用于向美国新闻通讯社分发,也不得用于在美国境内或向美国直接或间接、全部或部分发布出版、分发或传播
NESS-ZIONA, Israel, March 04, 2024 (GLOBE NEWSWIRE) -- Vaxil Bio Ltd. ("Vaxil" or the "Company") (TSXV:VXL) announces that further to press release from January 10, 2024 with Copper Bullet Mines Inc., ("CBMI"), the Company has received a notice of termination of the letter of intent between the Company and CBMI.
以色列NESS-ZIONA,2024年3月4日(GLOBE NEWSWIRE)——瓦西尔生物有限公司(“Vaxil” 或 “公司”)(TSXV: VXL)宣布,继2024年1月10日与Copper Bullet Mines Inc.(“CBMI”)发布新闻稿后,该公司已收到终止公司与CBMI之间的意向书的通知。
The Company will continue to actively explore other strategic options for maximizing shareholder value, including the continued development of Vaxil's existing assets.
公司将继续积极探索其他战略选择,以实现股东价值最大化,包括继续开发Vaxil的现有资产。
To this end, the Company is pleased to advise that the work performed by the Company together with Prof. Ayelet David, from Ben-Gurion University of the Negev ("BGU"), which demonstrated therapeutic success by prolonging the survival of mice treated with P-Esbp-DOX in a mouse model of aggressive liver metastasis of colorectal cancer (CRC) has now been published and is available for review in the journal NanoToday at the following website link:
为此,公司很高兴地告知,公司与内盖夫本古里安大学(“BGU”)的Ayelet David教授共同开展的研究已经发表,该研究延长了结直肠癌侵袭性肝转移(CRC)小鼠模型中接受p-ESBP-DOX治疗的小鼠存活期,从而证明了治疗上的成功以下网站链接:
The Company has an exclusive worldwide license agreement for the development and commercialization of this targeted cancer therapy with BGN Technologies, the technology transfer company of BGU. To the extent that a successful therapy is developed, the Company will pay BGU a royalty on sales.
该公司与BGU的技术转让公司BGN Technologies签订了全球独家许可协议,用于开发和商业化这种靶向癌症疗法。只要开发出成功的疗法,公司将向BGU支付销售特许权使用费。
ABOUT VAXIL
关于 VAXIL
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Vaxil是一家以色列免疫疗法生物技术公司,专注于其靶向主要癌症标志物和传染病的新方法。其主导产品Immucin成功完成了针对多发性骨髓瘤的1/2期临床试验,并获得了美国食品药品管理局和欧洲药品管理局的孤儿药地位。该公司的目标是继续开发Immucin、一种 COVID-19 和一种结核疫苗/治疗方法,该疫苗/疗法已显示出令人鼓舞的初步结果,并计划进行进一步的临床前评估。其他适应症和候选单抗正在评估中,可以单独使用免疫肿瘤学和传染病治疗,也可以与其他疗法联合使用。
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit, Vaxil's proprietary bioinformatic approach. These signal pepdies induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by "educating" or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil's mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
Vaxil利用关键蛋白质上信号肽结构域的独特特性,开发针对癌症靶标和传染病病原体的靶向疗法。这些信号肽结构域由Vaxil专有的生物信息学方法VaxHit识别。这些信号肽在广泛多样的 HLA 亚型中诱导强大的 T 细胞和 B 细胞反应,同时充当真正的通用新抗原。肽平台通过 “教育” 或特异性激活免疫系统来靶向这些细胞,以识别和攻击受影响的细胞。此外,Vaxil的mAb平台可以直接识别恶性细胞上表达的靶蛋白,并招募免疫系统的其他元素来裂解这些细胞。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多伦多证券交易所风险投资交易所及其监管服务提供商(该术语在多伦多证券交易所风险交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
Disclaimer: The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see ). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.
免责声明:TSX Venture Exchange Inc.决没有透露公司的案情,也没有批准或不批准本新闻稿的内容。本新闻稿包含前瞻性信息,涉及已知和未知的风险、不确定性和其他可能导致实际事件与当前预期存在重大差异的因素。公司不时在SEDAR上提交的文件中披露了可能导致实际业绩与公司预期存在重大差异的重要因素,包括资金的可用性、融资工作的结果、勘探活动的结果(见 )。提醒读者不要过分依赖这些前瞻性陈述,这些陈述仅代表截至本新闻稿发布之日。除非法律要求,否则公司不打算或承担任何更新或修改任何前瞻性陈述的意图或义务,无论是由于新信息、未来事件还是其他原因。本新闻稿不构成在美国或其他地方出售本文所述任何证券的卖出要约或邀请。这些证券过去和将来都不会在经修订的1933年《美国证券法》或任何州证券法中注册,除非注册或豁免,否则不得在美国或向美国个人发行或出售。
Contact Information
联系信息
For further information please visit or contact:
欲了解更多信息,请访问或联系:
Gadi Levin, CFO
info@vaxil-bio.com
647-558-5564
首席财务官加迪·莱文
info@vaxil-bio.com
647-558-5564